In research published today in Nucleic Acid Research, co-first author Seong Guk Park, PhD, and corresponding author Elizabeth Kellogg, PhD, St. Jude Department of Structural Biology, designed a high-throughput approach which allowed them to rapidly screen and optimize promising gene-editing tools called CASTs, uncovering mechanistic insights fundamental for further engineering.
Natural systems such as CRISPR-associated transposons (CASTs) offer a targetable, one-step way to edit genomes. However, adapting them for biomedical applications has been challenging. To address this limitation, scientists at St. Jude Children’s Research Hospital designed a screening approach to measure efficiency and specificity for thousands of CAST variants accurately. This high-throughput approach allowed the researchers to rapidly optimize promising candidate CASTs, uncovering mechanistic insights fundamental for further engineering and potential clinical use. The findings were published today in Nucleic Acid Research.
Discovered in 2017, CASTs integrate large pieces of DNA into the genome at locations defined by a given RNA sequence. They are highly specific in bacteria, their natural host, but they do not work as well in human cells.
For this reason, corresponding author Elizabeth Kellogg, PhD, St. Jude Department of Structural Biology, is keenly interested in engineering CASTs to be more applicable to humans and other organisms. To do so requires a quick way to evaluate the strengths and weaknesses of engineered CASTs.
“One major gap in understanding CASTs was not just measuring their overall activity, but also how accurately they integrate DNA at the intended locations,” Kellogg said. “There simply wasn’t a scalable way to characterize their specificity.”
CASTing call for specificity and efficiency
Researchers are exploring ways to engineer CASTs to be more applicable to humans and other organisms. This novel screening strategy provides a quick way to evaluate the strengths and weaknesses of engineered CASTs allowing for new routes to be explored more efficiently. Pictured is co-first author Jung-Un Park, PhD, University of California Berkely, formerly St. Jude.
To address this gap, the researchers devised a high-throughput screen to measure the relative activity and specificity of thousands of CAST variants in a single experiment. By focusing on a single subtype — the V-K CAST, which is notably less complex than others — they were able to make slight alterations to its proteins and rapidly screen the mutants.
“We wanted to screen a library with every possible single mutation to explore the mutational landscape of a CAST system,” said co-first author Seong Guk Park, PhD, Department of Structural Biology. “We didn’t focus on specific regions; instead, we tested them all to find mutations that could improve activity or specificity.”
After the V-K CAST mutational screening, the researchers combined several of the most promising mutations to see if their positive effect was additive. “With just a few mutations, activity increased fivefold,” Kellogg said. “We improved both specificity and activity without compromising either, which was not possible with previous strategies.”
Kellogg will continue working to improve the CAST design. With this screen now available, she is optimistic. “The natural system is very complicated, so we need to develop more minimal systems,” Kellogg said. “But this screen now enables us to be more ambitious with our protein design so that we can ultimately achieve this goal.”
Authors and funding
The study’s other first author is Jung-Un Park, University of California Berkeley and St. Jude. The study’s other authors are Esteban Dodero-Rojas, John Bryant Jr., and Geetha Sankaranarayanan, St. Jude.
The study was supported by the National Institutes of Health (5R01GM144566-02), the Pew Charitable Trusts, the Cystic Fibrosis Foundation, the Jane Coffin Childs Memorial Fund, the Korea Health Industry Development Institute (HI19C1095), the National Cancer Institute (P30-CA21765) and the American Lebanese Syrian Associated Charities (ALSAC), the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children’s Research Hospital is leading the way the world understands, treats, and cures childhood catastrophic diseases. From cancer to life-threatening blood disorders, neurological conditions, and infectious diseases, St. Jude is dedicated to advancing cures and means of prevention through groundbreaking research and compassionate care. Through global collaborations and innovative science, St. Jude is working to ensure that every child, everywhere, has the best chance at a healthy future. To learn more, visit stjude.org, read St. Jude Progress, a digital magazine, and follow St. Jude on social media at @stjuderesearch.